Speaker(s): 

Chichun Emily Sun DO, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Anil Singh, MD, Staff Member, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Discuss appropriate use of Alzheimer's disease (AD) biomarkers
• Compare the advantages and disadvantages of AD biomarkers
• Summarize key inclusion and exclusion criteria for disease=modifying therapy in early-stage Alzheimer's disease

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Anil Kumar Singh, MD, Roop Parlapalli, MD, FHM, FACP, Lakshmi Rani Gollamudi, MD, Christopher DeFrancesco PharmD, RPH, Mary Ellen Berry, PA-C, and Carlena Miller, CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None